Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Asset Utilization Ratio (2016 - 2025)

Historic Asset Utilization Ratio for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to 0.12.

  • Lineage Cell Therapeutics' Asset Utilization Ratio rose 3708.45% to 0.12 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.12, marking a year-over-year increase of 3708.45%. This contributed to the annual value of 0.09 for FY2024, which is 1137.13% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Asset Utilization Ratio of 0.12 as of Q3 2025, which was up 3708.45% from 0.11 recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Asset Utilization Ratio high stood at 0.47 for Q3 2022, and its period low was 0.01 during Q2 2021.
  • Its 5-year average for Asset Utilization Ratio is 0.15, with a median of 0.09 in 2024.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Asset Utilization Ratio surged by 307823.0% in 2022, and later crashed by 8287.2% in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Asset Utilization Ratio (Quarter) stood at 0.35 in 2021, then tumbled by 66.82% to 0.12 in 2022, then dropped by 25.17% to 0.09 in 2023, then increased by 4.86% to 0.09 in 2024, then soared by 32.4% to 0.12 in 2025.
  • Its Asset Utilization Ratio was 0.12 in Q3 2025, compared to 0.11 in Q2 2025 and 0.08 in Q1 2025.